

Rag1-KO(Rag1-EGFP)

Nomenclature B6;129S-*Rag1*^{tm1(loxP-EGFP-PolyA-loxP-Neo-loxP)Smoc}

Cat. NO. NM-KI-00069

Strain State Repository Live

Gene Summary

| Gene Symbol Rag1 | Synonyms | Rag-1 |
|---------------------|--|--------------------|
| | NCBI ID | <u>19373</u> |
| | MGI ID | <u>97848</u> |
| | Ensembl ID | ENSMUSG00000061311 |
| | Human Ortholog | RAG1 |
| | Human Ortholog Associated Diseases by GWAS | 奥门综合症、免疫缺陷综合症 |

Model Description

A loxP-EGFP-PolyA-loxP-Neo-loxP expression cassette was knocked into the Rag1 gene start codon site. As a Rag1 knockout mouse model, this stain can be used in subcutaneous inoculation of liver cancer tissues and tumor cells. Tumors can esaily form and grow. The amount of T and B lymphocytes in peripheral blood of mice was extremely low tested by FACS, which was comparable to or lower than that of Nude mice, and there was a significant difference compared with wild type mice. The pathological sections of HE staining of tumor tissues showed that the tumor sections of Rag1 KO mice and Nude mice were similar. This strain has the potential to replace Nude, NOD-SCID mice as a tumor-bearing mouse model.

Research Application: Immunodeficiency,tumor-bearing model

*Literature published using this strain should indicate: Rag1-KO(Rag1-EGFP) mice (Cat. NO. NM-KI-00069) were purchased from Shanghai Model Organisms Center, Inc..

Validation Data






Figure 1. Generation strategy of Rag1 gene knockout mice.




Figure 2 Splenocytes cells of C57BL/6J, NOD-SCID, Rag1-/-, and Rag2-/- mice were isolated. Fractions of T and B cells were characterized using flow cytometry.






Figure 3. Complete deletion of T and B cells in the blood of Rag1-KO/Rag2-KO mice.

(A) The peripheral blood samples of C57BL/6, Rag1-KO and Rag2-KO mice were collected to analyze their compositions of T, B and NK cells by FACS.(B) Statistical analysis of sorted cells.




Figure 4. Complete deletion of T and B cells in the spleen of Rag1-KO/Rag2-KO mice.

(A) The splenocytes of C57BL/6, Rag1-KO and Rag2-KO mice were collected to analyze their compositions of T, B and NK cells by FACS.(B) Statistical analysis of sorted cells.






Figure 5. Complete deletion of T and B cells in the thymus gland of Rag1-KO/Rag2-KO mice.

(A) The thymocyte of C57BL/6, Rag1-KO and Rag2-KO mice were collected to analyze their compositions of T, B and NK cells by FACS.(B) Statistical analysis of sorted cells.




Figure 6. The establishment of tumor models using A549 lung cancer cells is more effective in Rag1-/- or Rag2-/- mice.

Table 1. Blood routine tests in Rag1-KO(Rag1-EGFP).



| | | Rag1-KO; Male | Rag1-KO; Female |
|-----------|--------------------------|------------------|------------------|
| Parameter | Units | 8-10 weeks; n=10 | 8-10 weeks; n=10 |
| WBC | 103 cells/µL | 2.16±0.44 | 0.76±0.24 |
| RBC | 106 cells/μL | 9.69±0.09 | 10.13±0.09 |
| HGB | g/dL | 14.34±0.13 | 15.10±0.12 |
| HCT | % | 46.78±0.37 | 48.36±0.20 |
| MCV | fL | 48.27±0.28 | 47.76±0.31 |
| MCH | pg | 14.81±0.08 | 14.90±0.03 |
| MCHC | g/dL | 30.67±0.10 | 31.23±0.17 |
| PLT | 10 ⁶ cells/μL | 2252.00±70.30 | 1573.78±77.11 |
| RDW-SD | fL | 32.10±0.49 | 29.20±0.23 |
| RDW-CV | 96 | 21.42±0.21 | 20.57±0.17 |
| PDW | fL | 7.47±0.11 | 7.37±0.13 |
| MPV | fL | 6.79±0.08 | 6.66±0.08 |
| P-LCR | 96 | 5.22±0.31 | 4.67±0.33 |
| PCT | 96 | 1.53±0.05 | 1.05±0.08 |
| NEUT# | 103 cells/μL | 1.28±0.33 | 0.32±0.09 |
| LYMPH# | 103 cells/μL | 0.57±0.08 | 0.34±0.12 |
| MONO# | 103 cells/μL | 0.27±0.09 | 0.08±0.03 |
| EO# | 103 cells/μL | 0.02±0.00 | 0.01±0.01 |
| BASO# | 103 cells/μL | 0.02±0.01 | 0.01±0.01 |
| NEUT% | 96 | 54.72±4.84 | 46.99±5.04 |
| LYMPH% | 96 | 32.15±4.90 | 42.13±5.31 |
| MONO% | 96 | 11.24±1.19 | 8.79±1.27 |
| EO%(%) | % | 0.98±0.19 | 1.31±0.53 |
| BASO% | 96 | 0.91±0.51 | 0.78±0.39 |
| RET# | 106 cells/μL | 0.50±0.01 | 0.53±0.03 |
| RET% | % | 5.19±0.10 | 5.25±0.33 |
| LFR(%) | % | 42.78±0.95 | 42.93±1.28 |
| MFR(%) | % | 24.65±0.66 | 25.69±0.52 |
| HFR(%) | % | 32.57±1.49 | 31.38±1.25 |
| IRF(%) | % | 57.22±0.95 | 57.07±1.28 |

Table2. Blood biochemistry in Rag1-KO(Rag1-EGFP).



| Parameter | Units | Rag1-KO; Male | Rag1-KO; Female |
|-----------|--------|------------------|------------------|
| | | 8-10 weeks; n=10 | 8-10 weeks; n=10 |
| TP | g/L | 54.00±1.25 | 57.11±1.65 |
| ALB | g/L | 25.50±0.50 | 27.17±1.11 |
| ALP | U/L | 469.00±13.76 | 806.78±15.20 |
| ALT | U/L | 69.50±8.31 | 44.17±16.91 |
| AST | U/L | 191.00±36.25 | 223.06±62.00 |
| T-BIL | µmol/L | 1.62±0.15 | 1.76±0.66 |
| D-BIL | µmol/L | 1.78±0.28 | 7.65±4.93 |
| CHE | U/L | 4143.50±148.13 | 6539.22±205.63 |
| CRE | µmol/L | 20.97±0.66 | 21.77±1.31 |
| BUN | mmol/L | 10.10±0.44 | 8.17±0.61 |
| UA | µmol/L | 311.60±41.33 | 120.06±5.81 |
| тсно | mmol/L | 2.93±0.07 | 2.44±0.11 |
| TG | mmol/L | 1.04±0.06 | 0.39±0.05 |
| HDL | mmol/L | 2.62±0.11 | 2.12±0.22 |
| LDL | mmol/L | 1.92±0.03 | 2.25±0.16 |
| NEFA | mmol/L | 0.70±0.05 | 0.78±0.14 |
| LDH | U/L | 702.50±99.53 | 813.67±272.32 |
| СК | U/L | 1107.50±464.45 | 1915.67±500.47 |
| Hey | µmol/L | 11.45±0.98 | 13.78±0.88 |
| GLU | mmol/L | 16.94±0.87 | 9.49±0.60 |
| Ca | mmol/L | 3.18±0.05 | 2.79±0.05 |
| IP | mmol/L | 4.20±0.13 | 3.31±0.11 |
| Fe | µmol/L | 38.35±1.20 | 36.66±2.64 |
| CRP | mg/L | 0.46±0.26 | 0.27±0.16 |

Publications

<u>Programmed death protein 1 is essential for maintaining the anti-inflammatory function of infiltrating regulatory T cells in a murine spinal cord injury model</u>

References: Journal of Neuroimmunology

Peli1 negatively regulates noncanonical NF-κB signaling to restrain systemic lupus erythematosus

References: Nature Communications

<u>Interleukin-17 Regulates Neuron-Glial Communications, Synaptic Transmission, and Neuropathic Pain after Chemotherapy</u>

References: Cell Reports

<u>Tpl2 Protects Against Fulminant Hepatitis Through Mobilization of Myeloid-Derived Suppressor</u> Cells

References: Frontiers in Immunology



Gut Microbial Metabolite Pravastatin Attenuates Intestinal Ischemia/Reperfusion Injury Through Promoting IL-13 Release From Type II Innate Lymphoid Cells via IL-33/ST2 Signaling

References: Frontiers in Immunology